Novartis weighs in on biosimilar naming debate

01-11-2013 PMLiVEComments (0)


Novartis has filed a petition with US authorities urging them to retain the current system to name biosimilar medicines. As it stands, the Food and Drug Administration (FDA) requires that biosimilar medicines - a copy of a branded drug derived from ...

Read more on PMLiVE

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top